Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 Infection

NCT04860518 is registered in ClinicalTrials.gov with Faron Pharmaceuticals Ltd as lead sponsor.

NCT NCT04860518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 Infection
Lead sponsor
Faron Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Terminated
Start date
August 23, 2021
Completion date
April 4, 2022
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19